Drugs / H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00347672 | Jun 2006 → Jul 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00347672 ↗ |
| Known as | H5N1 VN 2004 AA ca | “We performed open-label trials to evaluate the safety, infectivity, and immunogenicity of H5N1 VN 2004 AA ca and H5N1 HK 2003 AA ca.” PMID 19540952 ↗ Jun 2009 |
| Known as | H5N1 VN 2004 AA ca vaccine | “The H5N1 VN 2004 AA ca vaccine virus was evaluated at dosages of 10(6.7) TCID(50) and 10(7.5) TCID(50), and the H5N1 HK 2003 AA ca vaccine was evaluated at a dosage of 10(7.5) TCID(50).” PMID 19540952 ↗ Jun 2009 |
| Known as | H5N1 VN 2004/AA vaccine | “Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose” NCT00347672 ↗ |
| Route | Intranasal | “Two doses were administered intranasally to healthy adults in isolation at 4-8 week intervals.” PMID 19540952 ↗ Jun 2009 |